Keep up-to-date with PrECOG by visiting our news page regularly.
After phase 2 trials showed promising survival for the combination of durvalumab during and after standard chemotherapy, collaborators in the US, Australia, and New Zealand open the phase 3 DREAM3R trial For Immediate Release March 17, 2021 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia—The DREAM3R phase three clinical trial is […]
Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination should advance to a randomized phase 3 study For Immediate Release May 20, 2020 Contact Diane Dragaud Director of Communications (215) 789-3631 Inquire by email Philadelphia, PA—PrECOG, LLC is reporting clinical efficacy and biomarker analyses from its single-arm phase two […]